Particle-Based therapies for antigen specific treatment of type 1 diabetes
- PMID: 36529362
- PMCID: PMC9841461
- DOI: 10.1016/j.ijpharm.2022.122500
Particle-Based therapies for antigen specific treatment of type 1 diabetes
Abstract
Type 1 diabetes mellitus (T1D) is the leading metabolic disorder in children worldwide. Over time, incidence rates have continued to rise with 20 million individuals affected globally by the autoimmune disease. The current standard of care is costly and time-consuming requiring daily injections of exogenous insulin. T1D is mediated by autoimmune effector responses targeting autoantigens expressed on pancreatic islet β-cells. One approach to treat T1D is to skew the immune system away from an effector response by taking an antigen-specific approach to heighten a regulatory response through a therapeutic vaccine. An antigen-specific approach has been shown with soluble agents, but the effects have been limited. Micro or nanoparticles have been used to deliver a variety of therapeutic agents including peptides and immunomodulatory therapies to immune cells. Particle-based systems can be used to deliver cargo into the cell and microparticles can passively target phagocytic cells. Further, surface modification and controlled release of encapsulated cargo can enhance delivery over soluble agents. The induction of antigen-specific immune tolerance is imperative for the treatment of autoimmune diseases such as T1D. This review highlights studies that utilize particle-based platforms for the treatment of T1D.
Keywords: Dendritic Cell; Pancreatic β cells; Polymeric particles; Regulatory T cell; Vaccines.
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction.Sci Rep. 2019 Nov 6;9(1):16103. doi: 10.1038/s41598-019-52331-1. Sci Rep. 2019. PMID: 31695065 Free PMC article.
-
Old Dog New Tricks: PLGA Microparticles as an Adjuvant for Insulin Peptide Fragment-Induced Immune Tolerance against Type 1 Diabetes.Mol Pharm. 2020 Sep 8;17(9):3513-3525. doi: 10.1021/acs.molpharmaceut.0c00525. Epub 2020 Aug 17. Mol Pharm. 2020. PMID: 32787283
-
Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.Adv Exp Med Biol. 2010;654:641-65. doi: 10.1007/978-90-481-3271-3_28. Adv Exp Med Biol. 2010. PMID: 20217518 Review.
-
In Vivo Insulin Peptide Autoantigen Delivery by Mannosylated Sodium Alginate Nanoparticles Delayed but Could Not Prevent the Onset of Type 1 Diabetes in Nonobese Diabetic Mice.Mol Pharm. 2021 Apr 5;18(4):1806-1818. doi: 10.1021/acs.molpharmaceut.1c00054. Epub 2021 Mar 18. Mol Pharm. 2021. PMID: 33734705
-
Pancreatic islet autoimmunity.Presse Med. 2012 Dec;41(12 P 2):e636-50. doi: 10.1016/j.lpm.2012.10.003. Epub 2012 Nov 22. Presse Med. 2012. PMID: 23182678 Review.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical